Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization

Abstract

The use of erythropoietic agents has been associated with an increased risk of venous thromboembolic events (VTEs), especially in patients with underlying malignancies. However, it is not known whether there is an increased risk of VTE associated with granulocyte growth factors. We reviewed 621 patients undergoing PBSC mobilization using granulocyte growth factors, alone or in combination with CY. Patients with a diagnosis of AL amyloidosis (AL: 114; 18%), multiple myeloma (MM: 278; 44%) Hodgkin lymphoma (HL: 20; 3%) or non-Hodgkin lymphoma (NHL: 209; 33%) were included. Symptomatic VTE occurred in six (0.97%) patients: two AL, two MM and two NHL. Of the six patients, two had pulmonary embolism, one developed deep vein thrombosis and three developed symptomatic catheter related thrombosis. Two patients with AL had heparin-induced thrombocytopenia and thrombosis. We found a low incidence of VTE among patients undergoing PBSC mobilization.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB . The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112: 504–510.

    Article  CAS  Google Scholar 

  2. Gonsalves A, Carrier M, Wells PS, McDiarmid SA, Huebsch LB, Allan DS . Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 2008; 6: 1468–1473.

    Article  CAS  Google Scholar 

  3. Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903–908.

    CAS  PubMed  Google Scholar 

  4. LeBlanc R, Roy J, Demers C, Vu L, Cantin G . A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 1999; 23: 991–996.

    Article  CAS  Google Scholar 

  5. Alegre A, Requena MJ, Fernandez-Villalta MJ, Orts M, Gilsanz F, Tomas JF et al. Quinton-Mahurkar catheter as short-term central venous access for PBSC collection: single-center experience of 370 aphereses in 110 patients. Bone Marrow Transplant 1996; 18: 865–869.

    CAS  PubMed  Google Scholar 

  6. Saif MW, Leitman SF, Cusack G, Horne M, Freifeld A, Venzon D et al. Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer. Ann Oncol 2004; 15: 1366–1372.

    Article  CAS  Google Scholar 

  7. Stephens LC, Haire WD, Tarantolo S, Reed E, Schmit-Pokorny K, Kessinger A et al. Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC). Transfus Sci 1997; 18: 187–193.

    Article  CAS  Google Scholar 

  8. Warkentin TE, Greinacher A, Koster A, Lincoff AM . Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S–380S.

    Article  CAS  Google Scholar 

  9. Murata M, Harada M, Kato S, Takahashi S, Ogawa H, Okamoto S et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999; 24: 1065–1071.

    Article  CAS  Google Scholar 

  10. Kuroiwa M, Okamura T, Kanaji T, Okamura S, Harada M, Niho Y . Effects of granulocyte colony-stimulating factor on the hemostatic system in healthy volunteers. Int J Hematol 1996; 63: 311–316.

    Article  CAS  Google Scholar 

  11. Carrier M, Tay J, Fergusson D, Wells PS . Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 2007; 5: 2552–2554.

    Article  CAS  Google Scholar 

  12. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009; 373: 567–574.

    Article  Google Scholar 

  13. Hong AP, Cook DJ, Sigouin CS, Warkentin TE . Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101: 3049–3051.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Kumar.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naina, H., Pruthi, R., Inwards, D. et al. Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. Bone Marrow Transplant 46, 291–293 (2011). https://doi.org/10.1038/bmt.2010.106

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.106

Keywords

This article is cited by

Search

Quick links